<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02454010</url>
  </required_header>
  <id_info>
    <org_study_id>FF21101US101</org_study_id>
    <nct_id>NCT02454010</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer</brief_title>
  <official_title>A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujifilm Pharmaceuticals U.S.A., Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujifilm Pharmaceuticals U.S.A., Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability in subjects who receive&#xD;
      FF-21101(111In) for dosimetry and FF-21101(90Y) for treatment of advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the safety and tolerability in subjects who receive&#xD;
      FF-21101(111In) for dosimetry and FF-21101(90Y) for treatment of advanced solid tumors. This&#xD;
      is an open label study that will recruit approx 70 patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of radio-labeled FF21101</measure>
    <time_frame>28 days</time_frame>
    <description>measured by number of patients with adverse events leading to discontinuation or number of patients with dose limiting toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients achieving overall response using Response Evaluation Criteria in Solid Tumors (RECIST v. 1.1)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Overall response rates are defined as the number of patients achieving a best response of complete response [CR], partial response [PR], stable disease [SD], or progressive disease [PD])</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients expressing CDH3 (human cadherin 3/P-cadherin) as a predictor of clinical activity</measure>
    <time_frame>Single sample taken at enrollment</time_frame>
    <description>measurement of CDH3 expression</description>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Lowest dose of FF-21101(90Y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2X Lowest dose of FF-21101(90Y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 2X the lowest dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3X Lowest dose of FF-21101(90Y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 3X the lowest dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4X Lowest dose of FF-21101(90Y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 4X the lowest dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5X Lowest dose of FF-21101(90Y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 5X the lowest dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase (Cohort 6), Ovarian</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the expansion phase, subjects in this cohort will be diagnosed with epithelial ovarian, peritoneal or fallopian tube carcinoma and will receive a dose of 25 mCi/m2 FF-21101(90Y)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase (Cohort 7), Adv Tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the expansion phase, subjects in this cohort will be diagnosed with triple negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), biliary cancer (cholangiocarcinoma or gall bladder carcinoma), pancreatic carcinoma, colorectal cancer and will receive a dose of 25 mCi/m2 FF-21101(90Y)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FF21101</intervention_name>
    <description>(90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)</description>
    <arm_group_label>2X Lowest dose of FF-21101(90Y)</arm_group_label>
    <arm_group_label>3X Lowest dose of FF-21101(90Y)</arm_group_label>
    <arm_group_label>4X Lowest dose of FF-21101(90Y)</arm_group_label>
    <arm_group_label>5X Lowest dose of FF-21101(90Y)</arm_group_label>
    <arm_group_label>Expansion Phase (Cohort 6), Ovarian</arm_group_label>
    <arm_group_label>Expansion Phase (Cohort 7), Adv Tumors</arm_group_label>
    <arm_group_label>Lowest dose of FF-21101(90Y)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females ≥ 18 years of age&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced solid tumor malignancy, refractory&#xD;
             or relapsed from prior therapy, or for whom no alternative therapy is available&#xD;
&#xD;
          -  At least 4 weeks beyond the last chemotherapy (or ≥ 5 half-lives for targeted agents,&#xD;
             whichever is shorter), radiotherapy, major surgery or experimental treatment and&#xD;
             recovered from all acute toxicities (≤ Grade 1)&#xD;
&#xD;
          -  Archival tumor sample available, or be willing to undergo a fresh tumor biopsy, prior&#xD;
             to study&#xD;
&#xD;
          -  At least one measurable disease site that meets target lesion requirements&#xD;
&#xD;
          -  Adequate performance status: Eastern Cooperative Oncology Group (ECOG) ≤ 2&#xD;
&#xD;
          -  Life expectancy of ≥ 3 months&#xD;
&#xD;
          -  Adequate hematologic parameters without ongoing transfusional support:&#xD;
&#xD;
          -  Negative serum pregnancy test&#xD;
&#xD;
          -  Ability to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous radioimmunotherapy. Previous antibody-based therapy is allowed as long as ≥&#xD;
             28 days has elapsed from last dose to study treatment.&#xD;
&#xD;
          -  Prior radiation to &gt; 30% of the red marrow or to maximal tolerable level for any organ&#xD;
&#xD;
          -  Serious cardiac condition within the last 6 months&#xD;
&#xD;
          -  Concomitant medication(s) that may cause QTc prolongation or induce Torsades de&#xD;
             Pointes, with the exception of antimicrobials that are considered to be essential for&#xD;
             care of the patient&#xD;
&#xD;
          -  History of retinal degenerative disease, history of uveitis, history of retinal vein&#xD;
             occlusion (RVO), or any eye condition that would be considered a risk factor for RVO&#xD;
             or has medically relevant abnormalities identified on screening ophthalmologic&#xD;
             examination&#xD;
&#xD;
          -  Active central nervous system (CNS) malignant disease in subjects with a history of&#xD;
             CNS malignancy. Subjects with stable, prior, or currently treated brain metastases are&#xD;
             allowed.&#xD;
&#xD;
          -  Known positive for human immunodeficiency virus (HIV), hepatitis B virus surface&#xD;
             antigen (HBsAg) or hepatitis C virus (HCV)&#xD;
&#xD;
          -  Known autoimmune disease&#xD;
&#xD;
          -  Active infection requiring intravenous (IV) antibiotic usage within the last week&#xD;
             prior to the dosimetry portion of the study&#xD;
&#xD;
          -  Corticosteroid use within 2 weeks of study treatment&#xD;
&#xD;
          -  Any other medical intervention or other condition which, in the opinion of the&#xD;
             Principal Investigator, could compromise adherence with study requirements or confound&#xD;
             the interpretation of study results&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Winship Cancer Institute - Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University - Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 4, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

